A Phase 1 interventional study of KT501 in Rheumatoid Arthritis (RA), sponsored by Kali Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Kali Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Arthritis, Rheumatoid with a site in Australia — 16 open to participants now, 21 under way, 3 of them phase 3. Arthritis, Rheumatoid · Australia.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, this one is the 133rd largest by planned enrollment of the 140 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 4 of the 20 other live ones, and was the 148th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →16 of the 154 studies in Arthritis, Rheumatoid with a site in Australia are open now. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in Australia
Ages 18–75 · Healthy volunteers
The Bionics Institute of Australia · Sites in Australia
Ages 18–75
Candid Therapeutics · Sites in Australia
Ages 18–65 · Healthy volunteers
Kali Therapeutics, Inc. · Sites in Australia, New Zealand
Ages 18–75
Seismic Therapeutic AU Pty Ltd · Sites in Australia
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 30 · Phase 3 72 · Phase 4 13
First in 2000; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 469 across the 140 interventional studies, 559 across the 13 observational. Of the 131 that completed or were terminated, 94 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 154 have an industry lead sponsor. The 10 most frequent:
Kali Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Kali Therapeutics, Inc. has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
6 of the studies in Arthritis, Rheumatoid with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT07234773Kali Therapeutics, Inc.A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). | 2027-02 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT07017686The Bionics Institute of AustraliaThe Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis | 2027-09 |
| NCT07455578Seismic Therapeutic AU Pty LtdStudy of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 154 studies in Arthritis, Rheumatoid with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of KT501 administered subcutaneously to participants with Rheumatoid Arthritis (RA).
This is a Phase 1, open-label, first-in-human dose escalation study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic of KT501 by a single subcutaneous administration in participants with Rheumatoid Arthritis (RA).
Up to a total of 5 cohorts with up to approximately 24 participants in total with RA will be enrolled. All participants will receive a single dose of KT501 on Day 1 and followed up until Week 12. For any participants with B cells lower than baseline level or lower limit quantification, whichever is lower, additional B cell follow up is required up to Week 48 after the study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KT501 Subcutaneous Injection Dose Level 1
Drug: KT501
KT501 Subcutaneous Injection Dose Level 2
Drug: KT501
KT501 Subcutaneous Injection Dose Level 3
Drug: KT501
KT501 Subcutaneous Injection Dose Level 4
Drug: KT501
KT501 Subcutaneous Injection Dose Level 5
Drug: KT501
KT501 is a monoclonal antibody that depletes B cells including plasma cells by targeting CD19, BCMA and CD3.
Incidence of Adverse Events
Incidence and severity of Adverse Events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0.
Time frame: From Baseline Up to 12 weeks
Incidence of Cytokine-release Syndrome (CRS)
Incidence and severity of CRS with severity determined according to the 2019 American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus grading criteria
Time frame: From Baseline Up to 12 Weeks
Changes in Pulse Rate from Baseline
Vital signs: Changes in Pulse Rate from Baseline
Time frame: From Baseline Up to 12 Weeks
Changes in Respiratory Rate from Baseline
Vital Signs: Changes in Respiratory Rate from Baseline
Time frame: From Baseline to 12 Weeks
Changes in Blood Pressure from Baseline
Vital Signs: Changes in Blood Pressure from Baseline
Time frame: From Baseline Up to Week 12
Changes in Temperature from Baseline
Vital Signs: Changes in Body Temperature from Baseline
Time frame: From Baseline to 12 Weeks
Changes in Hematology Clinical Laboratory Results from Baseline
Hematology: Changes in results from Baseline
Time frame: From Baseline Up to 12 Weeks
Changes in Chemistry Clinical Laboratory Results from Baseline
Chemistry: Changes in results from Baseline
Time frame: From Baseline Up to 12 Weeks
Changes in Urinalysis Clinical Laboratory Results from Baseline
Urinalysis: Changes in results from Baseline
Time frame: From Baseline Up to 12 Weeks
Changes in Coagulation Clinical Laboratory Results from Baseline
Coagulation: Changes in results from Baseline
Time frame: From Baseline Up to 12 Weeks
Serum Concentrations of KT501
Blood samples will be collected at specific time points for calculating serum concentrations of KT501
Time frame: Pre-dose and 6 hours post-dose on Day 1; Day 2, 3, 4, 5, 8, 11, 15, 22, 29, 43, 57 and 85.
Incidence of Treatment-induced Anti-Drug Antibodies (ADAs)
For Immunogenicity: Incidence of participants with treatment induced Anti-Drug Antibodies (ADA)
Time frame: Pre-dose and on Day 1; Day 8, 11, 15, 22, 29, 43, 57 and 85.
To Determine Cmax
Maximum observed serum KT501 concentration
Time frame: Day 1 - Day 85
To Determine Tmax, Derived from Serum Concentration of each Dose of KT501
Time to maximum observed concentration
Time frame: Day 1 - Day 85
Area Under the Serum-concentration Time Curve (AUC) from Time Zero to the Last Timepoint with Measurable Analyte Concentration (AUC0-t)
Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (AUClast)
Time frame: Day 1 - Day 85
AUC from Time Zero to Infinity (AUCinf)
Area under the plasma concentration versus time curve (AUC) from time 0 extrapolated to infinity
Time frame: Day 1 - Day 85
To Determine Terminal Half-Life (T1/2)
Terminal elimination half life summarized by dosing regimen
Time frame: Day 1 - Day 85
Total Body Clearance (CL/F)
CL is the measure of the rate at which a drug is metabolized or eliminated by normal biological processes
Time frame: Day 1 - Day 85
Volume of Distribution During the Terminal Phase (Vz/F)
Vz is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Time frame: Day 1 - Day 85
Change in Levels of B Cell Count
Pharmacodynamics: Change in levels of B cell counts measured at specific timepoints
Time frame: Pre-dose on Day 1; Day 2, 3, 4, 5, 8, 11, 15, 22, 29, 43, 57 and 85.
Duration of B Cell Depletion
Pharmacodynamics: The duration of B cell depletion measured from Baseline
Time frame: Day 1 - Day 85
Change in Levels of Acute Inflammatory Markers
Pharmacodynamics: Change in levels of acute Inflammatory markers (C-reactive protein (CRP) and CRS-related cytokines at specific timepoints
Time frame: Pre-dose and 6 hours post-dose on Day 1; Day 2, 3, 4, 5, 8, 15, 22, 29,, 57 and 85.
Changes in Blood Pressure from Baseline
Vital Signs: Changes in Blood Pressure from Baseline
Time frame: From Baseline to 12 Weeks
Plan to share: No — This is a Phase 1 trial.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 11 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kali Therapeutics, Inc.